Ongoing Trials in Europe - ESOTA — ESO Trials Alliance

Ongoing ESOTA Trials

The aim of the Trials Network Committee is to facilitate academic clinical stroke research in Europe.

Within the networks various trials are actively recruiting. We would like to refer to the ‘Member Networks’ page to find more information about clinical studies within each network. Below you can find a link to clinicaltrials.gov which contains an overview of clinical stroke trials in all European countries.

We would also like to inform researchers about funding opportunities in Europe and information about insurance arrangements. These documents are currently being updated and will be uploaded shortly.

Investigators will find the following resources:

Database of ongoing stroke research: A repository of > 100 ongoing clinical stroke studies running in two or more European countries, including information about the coordinating investigators behind these trials. [click here]

Information about regulatory systems: Overview of competent authorities and research ethics committees in Europe, with links to the legislation for clinical trials in the different countries. [click here]

Information about insurance arrangements: Overview of insurance arrangements for multi-national clinical trials. [click here]

An overview of relevant courses and other resources organised and provided by each network can be found on the webpages of the national networks. [click here]

Existing trials collaborating with ESOTA networks

COIchine for prevention of Vascular Inflammation in Non-CardioEmbolic stroke (CONVINCE)

PI: Prof Peter Kelly, U College Dublin – Ireland
Colchicine plus usal care versus usal care alone after ischaemic stroke

Status (as of 21 January 2022):
Total number of randomised patients: 2606
Total number of randomised patients (ESOTA member countries): 2354
UK: 1043
Ireland: 433
Germany: 316
Belgium: 294
Spain: 235
Switzerland: 18
Netherlands: 15

Recruitment will close in Summer 2022 and last patient visits will be in December 2023.

Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillation (ELAN)

PI: Prof Urs Fischer, Inselspital (University Hospital) Bern – Switzerland
Early versus guideline-based introduction of direct oral anticoagulants after ischaemic stroke with atrial fibrillation

Status (as of 19 January 2022):
Total number of randomised patients: 1514
Total number of randomised patients (ESOTA member countries): 1141
Switzerland: 463
United Kingdom: 430
Belgium: 132
Germany: 101
Ireland: 15

Recruitment is currently ongoing in 90 sites in 14 countries (Switzerland, Germany, Austria, Greece, UK, Ireland, Belgium, Norway, Finland, Slovakia, Portugal, Israel, India, Japan)

Trials in planning phase collaborating with ESOTA networks

TICH-3

PI: Prof Nikola Sprigg, U Nottingham – UK
Tranexamic acid vs placebo for acute non-traumatic ICH <4.5 hours onset Status: UK = Open and recruiting, current participants = 3; International = in set up - first recruitment late 2022 (April 2022) New sites/investigators contact tich-3@nottingham.ac.uk

ASPIRING (Antiplatelet Secondary Prevention International Randomised trial after Intracerebralhaemorrhage)

PI: Prof Rustam al-Shahi Salman, University of Edinburg – UK
Antiplatelet therapy versus usual care for prevention of occlusive vascular events after ICH
Status: funding applications under way (April 2022)

European blood pressure intensive control after stroke – pilot trial (EPICS-Pilot)

PI: Prof Peter Kelly, University College Dublin – Ireland
Intensive versus guideline-based systolic blood pressure reduction after ischaemic stroke
Status: working on ethics applications (September 2022)